Menu Search
Equities

Hyperfine Inc

HYPR:NMQ

Hyperfine Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.04
  • Today's Change0.08 / 8.33%
  • Shares traded35.00
  • 1 Year change-49.76%
  • Beta0.8258
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Hyperfine Inc have a median target of 1.20, with a high estimate of 1.50 and a low estimate of 1.00. The median estimate represents a 15.38% increase from the last price of 1.04.
High44.2%1.50
Med15.4%1.20
Low-3.8%1.00

Earnings history & estimates in USD

On Aug 08, 2024, Hyperfine Inc reported 2nd quarter 2024 losses of -0.14 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 2nd quarter results by 6.67%.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+1.67%
Hyperfine Inc reported annual 2023 losses of -0.62 per share on Mar 21, 2024.
Average growth rate+40.38%
More ▼

Revenue history & estimates in USD

Hyperfine Inc had 2nd quarter 2024 revenues of 3.63m. This bettered the 3.26m consensus of the 3 analysts covering the company. This was 70.31% above the prior year's 2nd quarter results.
Average growth rate+4.27%
Hyperfine Inc had revenues for the full year 2023 of 11.03m. This was 61.90% above the prior year's results.
Average growth rate+61.90%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.